Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1518387

Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: A case report and review of the literature

Provisionally accepted
Yanhong Tan Yanhong Tan *Yang Xu Yang Xu *Yuying Fan Yuying Fan *Sijin Liu Sijin Liu *Jianmei Chang Jianmei Chang *Caifeng Guo Caifeng Guo *Lanhui Chen Lanhui Chen *Wenzheng Guo Wenzheng Guo *Jinwen Dang Jinwen Dang *Hongwei Wang Hongwei Wang *
  • Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China

The final, formatted version of the article will be published soon.

    The coexistence of three or more transcripts in one patient with chronic myeloid leukemia (CML) is rarely reported. Thus, the disease progression and drug response are still unknown. This case report aimed to explore the drug response of CML with variant transcripts and to enrich the clinical treatment of rare types of CML. A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four BCR::ABL1 transcripts, including variant e16a2(V-e16a2), variant e13a2(V-e13a2), classical e13a2, and e14a2 transcripts. The patient was treated with flumatinib, a tyrosine kinase inhibitor (TKI).The variant transcripts reported exhibited a favorable response to TKI, and attention should be directed toward monitoring variant transcripts.

    Keywords: chronic myelogenous leukemia, BCR::ABL1, e16a2 transcripts, variant transcript, tyrosine kinase inhibitors

    Received: 28 Oct 2024; Accepted: 26 Nov 2024.

    Copyright: © 2024 Tan, Xu, Fan, Liu, Chang, Guo, Chen, Guo, Dang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yanhong Tan, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Yang Xu, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Yuying Fan, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Sijin Liu, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Jianmei Chang, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Caifeng Guo, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Lanhui Chen, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Wenzheng Guo, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Jinwen Dang, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
    Hongwei Wang, Institute of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.